Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 3/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534122 | 0.87 | GSTO1 (0.34) | GSTO1MCL1F2HDAC1HDAC8 | |
| SCHEMBL534121 | 0.87 | GSTO1 (0.34) | GSTO1MCL1F2HDAC1HDAC8 | |
| SCHEMBL533622 | 0.83 | GRM5 (0.36) | GSTO1MCL1F2 | |
| SCHEMBL534621 | 0.81 | GSTO1 (0.34) | GSTO1MCL1F2HDAC1HDAC8 | |
| SCHEMBL28462362 | 0.80 | FGFR4 (0.46) | FGFR4TERT | |
| SCHEMBL534536 | 0.80 | NR1H2 (0.34) | GSTO1MCL1F2HDAC1HDAC8 | |
| SCHEMBL534154 | 0.77 | CYP1A2 (0.52) | — | |
| Formic Acid Methyl Ester SCHEMBL31027415 | 0.77 | FGFR4 (0.39) | FGFR4TERT | |
| SCHEMBL7500028 | 0.76 | POLB (0.52) | — | |
| SCHEMBL6353530 | 0.76 | NCF1 (0.42) | GSTO1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676720-B2 | Substituted biaryl compound | UBE INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160213657-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE INDUSTRIES, LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| EP-3042656-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE Industries, Ltd. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2980075-A1 | SUBSTITUTED BIARYL COMPOUND | UBE Industries, Ltd. (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2476668-B1 | ANILINE COMPOUNDS | UBE INDUSTRIES (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2476668-A1 | ANILINE COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | GSTO1 1723/4885FGFR4 4102/4885MCL1 4178/4885 |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | FIBP, FGF2, FGFR2 | GSTO1 1279/4885FGFR4 21/4885MCL1 2346/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | GSTO1 2621/4885FGFR4 3188/4885MCL1 4852/4885 |
| US-20160213657-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | CFTR, ADRB3, ADRB2 | GSTO1 517/4885FGFR4 2601/4885MCL1 4850/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | GSTO1 2686/4885FGFR4 3091/4885MCL1 4868/4885 |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | GSTO1 3640/4885FGFR4 4380/4885MCL1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.